Travoprost - Glaukos
Alternative Names: iDose TR; iDose TR - Glaukos; iDose Travoprost; Travoprost implant - Glaukos; Travoprost intracameral implant – Glaukos; Travoprost intraocular implant – GlaukosLatest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator Dose medical corporation
- Developer Glaukos Corporation
- Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 19 Jun 2024 Glaukos completes a phase III trial for Open-angle glaucoma and Ocular hypertension in USA (NCT03868124)
- 02 Apr 2024 Glaukos completes a phase III trial for Open-angle glaucoma and Ocular hypertension in USA (Intraocular) (NCT03519386)
- 26 Mar 2024 Launched for Ocular hypertension in USA (Intraocular) prior to March 2024